Replies to post #124030 on Biotech Values

[genisi]

With regards to perifosine and colorectal cancer, it's a shame that the phase II trial results have not been published.

The results of the phase II study of perifosine in colorectal cancer were published in JCO:

http://jco.ascopubs.org/content/early/2011/10/03/JCO.2011.36.1980.abstract

[mcbio]

The trial was very small (n = 38), but on the positive side both TTP and OS were significantly different. If the phase III trial is successful, it will address a sizeable unmet need, i.e. the ~40% of refractory CRC patients who carry KRAS mutations. It would also provide a fourth line option for KRAS wild-type patients, but I think that is likely to be a smaller market.

Where do you get that perifosine works specifically in KRAS CRC patients? I thought all their data to date is just in a general mCRC patient population and not specifically targeted to KRAS CRC patients.